BeOne Medicines (ONC) EBIT (2015 - 2026)

BeOne Medicines (ONC) has 12 years of EBIT data on file, last reported at $249.9 million in Q1 2026.

• On a quarterly basis, EBIT rose 2150.96% year-over-year to $249.9 million in Q1 2026; TTM through Mar 2026 was $685.9 million, a 331.93% increase from a year earlier, with the FY2025 full-year figure at $447.1 million, up 178.69% from the prior year.
• EBIT for Q1 2026 stood at $249.9 million, up from $185.0 million in the prior quarter.
• Over the last five years, EBIT for ONC reached as high as $249.9 million in Q1 2026 and fell as low as -$468.6 million in Q4 2022.
• Historically, EBIT has averaged -$168.7 million across 5 years, with a median of -$134.0 million in 2023.
• Across the five-year window, EBIT sank 731.76% in 2022 and jumped 2150.96% in 2026, its largest moves.
• Year by year, EBIT stood at -$468.6 million in 2022, then grew by 18.1% to -$383.8 million in 2023, then soared by 79.31% to -$79.4 million in 2024, then soared by 332.97% to $185.0 million in 2025, then surged by 35.06% to $249.9 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were $249.9 million in Q1 2026, $185.0 million in Q4 2025, and $163.1 million in Q3 2025.